Literature DB >> 27427516

Very low doses of ionizing radiation and redox associated modifiers affect survivin-associated changes in radiation sensitivity.

Richard C Miller1, Jeffrey S Murley1, Alfred W Rademaker2, Gayle E Woloschak3, Jian Jian Li4, Ralph R Weichselbaum1, David J Grdina5.   

Abstract

Exposure of cells to a dose of ionizing radiation as low as 5mGy can induce changes in radiation sensitivity expressed by cells exposed to subsequent higher doses at later times. This is referred to as an adaptive effect. We describe a unique survivin-associated adaptive response in which increased radiation resistance or sensitization of cells can be induced by exposure to 5mGy or to the reactive oxygen species (ROS) generating drug Emodin (1,3,8-trihydroxy-6-methylanthraquinone), a naturally occurring anthraquinone. The purpose of this study was to determine the role of ROS generating processes in affecting both the intracellular localization of the inhibitor of apoptosis protein survivin and its subsequent effect on radiation response in the presence or absence of the anti-oxidant N-acetyl-L-cysteine (NAC). Experiments were performed using two well characterized murine sarcomas: SA-NH p53 wild-type (WT) and FSa p53 mutant (Mut), grown either in culture or as solid tumors in the right hind legs of C3H mice. Doses of 5mGy or 50μM Emodin were used to induce changes in the response of these tumor cells to higher radiation exposures using a multi-dosing paradigm. Effects on radiation sensitivity were determined for SA-NH and FSa cells as a function of survivin translocation either to the cytoplasm or nucleus in the presence or absence of 10mM NAC treatment. In vitro survival assays (2Gy per fraction, two once daily fractions) and tumor growth delay (TGD) (5Gy per fraction, five once daily fractions) studies were performed. Intracellular localization of survivin was determined by enzyme-linked immunosorbent assay (ELISA) and correlated to survival response and treatment conditions. 2Gy alone had no effect on intracellular translocation of survivin. When preceded 15min earlier by 5mGy or Emodin exposures, survivin became elevated in the cytoplasm of p53 WT SA-NH as compared to the nuclei of p53 Mut FSa cells. SA-NH cells transfected with p53 small interfering RNA (siRNA), in contrast, responded similarly to p53 Mut FSa cells by becoming more radiation sensitive if exposed to 5mGy prior to each 2Gy irradiation. In contrast to their respective responses to five once daily 5Gy fractions, SA-NH tumors were protected by 5mGy exposures administered 15min prior to each daily 5Gy dose as evidenced by a more rapid growth (1.9 day decrease in TGD, P=0.032), while FSa tumors were sensitized, growing at a much slower rate (4.5 day increase in TGD, P<0.001). Exposure of SA-NH and FSa tumor cells to 10mM NAC inhibited the ability of 5mGy and Emodin to induce intracellular translocation of survivin and the corresponding altered adaptive survival response. The survivin-associated adaptive response can be induced following a multi-dosing scheme in which very low radiation doses are followed shortly thereafter by higher doses consistent with a standard image guided radiotherapy protocol that is currently widely used in the treatment of cancer. While induced by exposure to ROS generating stresses, the ultimate expression of changes in radiation response is dependent upon the bi-functionality of the tumor associated protein survivin and its intracellular translocation.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adaptive response; Emodin; Radiation response; Reactive oxygen species; Survivin; p53

Mesh:

Substances:

Year:  2016        PMID: 27427516      PMCID: PMC6764831          DOI: 10.1016/j.freeradbiomed.2016.07.009

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  32 in total

1.  Low-dose radiation: thresholds, bystander effects, and adaptive responses.

Authors:  William M Bonner
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-18       Impact factor: 11.205

2.  The strategy for coupling the RanGTP gradient to nuclear protein export.

Authors:  Attila Becskei; Iain W Mattaj
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-31       Impact factor: 11.205

Review 3.  Nuclear or cytoplasmic expression of survivin: what is the significance?

Authors:  Fengzhi Li; Jie Yang; Nithya Ramnath; Milind M Javle; Dongfeng Tan
Journal:  Int J Cancer       Date:  2005-04-20       Impact factor: 7.396

Review 4.  Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential.

Authors:  Roland H Stauber; Wolf Mann; Shirley K Knauer
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701

Review 5.  Molecular mechanism of emodin action: transition from laxative ingredient to an antitumor agent.

Authors:  Gopal Srinivas; Suboj Babykutty; Priya Prasanna Sathiadevan; Priya Srinivas
Journal:  Med Res Rev       Date:  2007-09       Impact factor: 12.944

6.  Chemopreventive doses of amifostine confer no cytoprotection to tumor nodules growing in the lungs of mice treated with cyclophosphamide.

Authors:  D J Grdina; N Hunter; Y Kataoka; J S Murley; L Milas
Journal:  Semin Oncol       Date:  1999-04       Impact factor: 4.929

7.  Generation of free radicals by emodic acid and its [D-Lys6]GnRH-conjugate.

Authors:  S Rahimipour; I Bilkis; V Péron; G Gescheidt; F Barbosa; Y Mazur; Y Koch; L Weiner; M Fridkin
Journal:  Photochem Photobiol       Date:  2001-08       Impact factor: 3.421

Review 8.  Survivin: a bifunctional inhibitor of apoptosis protein.

Authors:  M E Johnson; E W Howerth
Journal:  Vet Pathol       Date:  2004-11       Impact factor: 2.221

9.  Delayed cytoprotection after enhancement of Sod2 (MnSOD) gene expression in SA-NH mouse sarcoma cells exposed to WR-1065, the active metabolite of amifostine.

Authors:  Jeffrey S Murley; Yasushi Kataoka; Christine J Weydert; Larry W Oberley; David J Grdina
Journal:  Radiat Res       Date:  2002-07       Impact factor: 2.841

Review 10.  Survivin's dual role: an export's view.

Authors:  Shirley K Knauer; Wolf Mann; Roland H Stauber
Journal:  Cell Cycle       Date:  2007-03-21       Impact factor: 4.534

View more
  3 in total

1.  TP53 Mutational Status and ROS Effect the Expression of the Survivin-Associated Radio-Adaptive Response.

Authors:  Jeffrey S Murley; Richard C Miller; Ralph R Weichselbaum; David J Grdina
Journal:  Radiat Res       Date:  2017-08-16       Impact factor: 2.841

2.  Altered expression of a metformin-mediated radiation response in SA-NH and FSa tumor cells treated under in vitro and in vivo growth conditions.

Authors:  Jeffrey S Murley; Richard C Miller; Raziye Rana Senlik; Alfred W Rademaker; David J Grdina
Journal:  Int J Radiat Biol       Date:  2017-03-28       Impact factor: 2.694

Review 3.  Nutraceutical Compounds as Sensitizers for Cancer Treatment in Radiation Therapy.

Authors:  Marco Calvaruso; Gaia Pucci; Rosa Musso; Valentina Bravatà; Francesco P Cammarata; Giorgio Russo; Giusi I Forte; Luigi Minafra
Journal:  Int J Mol Sci       Date:  2019-10-23       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.